These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 22736481)

  • 21. Opposing Effects of Cannabidiol in Patient-derived Neuroendocrine Tumor, Pheochromocytoma/Paraganglioma Primary Cultures.
    Wang K; Schober L; Fischer A; Bechmann N; Maurer J; Peischer L; Reul A; Hantel C; Reincke M; Beuschlein F; Robledo M; Mohr H; Pellegata NS; Schilbach K; Knösel T; Ilmer M; Angele M; Kroiss M; Maccio U; Broglie-Däppen M; Vetter D; Lehmann K; Pacak K; Grossman AB; Auernhammer CJ; Zitzmann K; Nölting S
    J Clin Endocrinol Metab; 2024 Oct; 109(11):2892-2904. PubMed ID: 38605427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phaeochromocytomas and paragangliomas: A difference in disease behaviour and clinical outcomes.
    Ezzat Abdel-Aziz T; Prete F; Conway G; Gaze M; Bomanji J; Bouloux P; Khoo B; Caplin M; Mushtaq I; Smart J; Kurzawinski TR
    J Surg Oncol; 2015 Oct; 112(5):486-91. PubMed ID: 26337393
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pheochromocytomas and extra-adrenal paragangliomas detected by screening in patients with SDHD-associated head-and-neck paragangliomas.
    Havekes B; van der Klaauw AA; Weiss MM; Jansen JC; van der Mey AG; Vriends AH; Bonsing BA; Romijn JA; Corssmit EP
    Endocr Relat Cancer; 2009 Jun; 16(2):527-36. PubMed ID: 19289533
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Everolimus for advanced pancreatic neuroendocrine tumours: a subgroup analysis evaluating Japanese patients in the RADIANT-3 trial.
    Ito T; Okusaka T; Ikeda M; Igarashi H; Morizane C; Nakachi K; Tajima T; Kasuga A; Fujita Y; Furuse J
    Jpn J Clin Oncol; 2012 Oct; 42(10):903-11. PubMed ID: 22859827
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pheochromocytoma and sympathetic paragangliomas].
    Zollinger R; Hedinger C
    Schweiz Med Wochenschr; 1983 Jul; 113(30):1057-65. PubMed ID: 6623024
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term everolimus treatment of patients with pancreatic neuroendocrine tumors.
    Wolin EM
    Chemotherapy; 2014; 60(3):143-50. PubMed ID: 25766415
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pheochromocytoma and paraganglioma in children: a review of medical and surgical management at a tertiary care center.
    Pham TH; Moir C; Thompson GB; Zarroug AE; Hamner CE; Farley D; van Heerden J; Lteif AN; Young WF
    Pediatrics; 2006 Sep; 118(3):1109-17. PubMed ID: 16951005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I trial of everolimus plus sorafenib for patients with advanced renal cell cancer.
    Amato RJ; Flaherty AL; Stepankiw M
    Clin Genitourin Cancer; 2012 Mar; 10(1):26-31. PubMed ID: 22169794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world study of everolimus in advanced progressive neuroendocrine tumors.
    Panzuto F; Rinzivillo M; Fazio N; de Braud F; Luppi G; Zatelli MC; Lugli F; Tomassetti P; Riccardi F; Nuzzo C; Brizzi MP; Faggiano A; Zaniboni A; Nobili E; Pastorelli D; Cascinu S; Merlano M; Chiara S; Antonuzzo L; Funaioli C; Spada F; Pusceddu S; Fontana A; Ambrosio MR; Cassano A; Campana D; Cartenì G; Appetecchia M; Berruti A; Colao A; Falconi M; Delle Fave G
    Oncologist; 2014 Sep; 19(9):966-74. PubMed ID: 25117065
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas.
    Ayala-Ramirez M; Chougnet CN; Habra MA; Palmer JL; Leboulleux S; Cabanillas ME; Caramella C; Anderson P; Al Ghuzlan A; Waguespack SG; Deandreis D; Baudin E; Jimenez C
    J Clin Endocrinol Metab; 2012 Nov; 97(11):4040-50. PubMed ID: 22965939
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors.
    Frank M; Klose KJ; Wied M; Ishaque N; Schade-Brittinger C; Arnold R
    Am J Gastroenterol; 1999 May; 94(5):1381-7. PubMed ID: 10235222
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment for Malignant Pheochromocytomas and Paragangliomas: 5 Years of Progress.
    Jimenez P; Tatsui C; Jessop A; Thosani S; Jimenez C
    Curr Oncol Rep; 2017 Oct; 19(12):83. PubMed ID: 29081018
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma.
    Harzstark AL; Small EJ; Weinberg VK; Sun J; Ryan CJ; Lin AM; Fong L; Brocks DR; Rosenberg JE
    Cancer; 2011 Sep; 117(18):4194-200. PubMed ID: 21387258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Surgical experience with nonfunctioning neuroendocrine tumors of the pancreas.
    Matthews BD; Heniford BT; Reardon PR; Brunicardi FC; Greene FL
    Am Surg; 2000 Dec; 66(12):1116-22; discussion 1122-3. PubMed ID: 11149582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomas.
    Pierre C; Agopiantz M; Brunaud L; Battaglia-Hsu SF; Max A; Pouget C; Nomine C; Lomazzi S; Vignaud JM; Weryha G; Oussalah A; Gauchotte G; Busby-Venner H
    Virchows Arch; 2019 Jun; 474(6):721-734. PubMed ID: 30868297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endoscopic treatment of solitary, bilateral, multiple, and recurrent pheochromocytomas and paragangliomas.
    Walz MK; Peitgen K; Neumann HP; Janssen OE; Philipp T; Mann K
    World J Surg; 2002 Aug; 26(8):1005-12. PubMed ID: 12045858
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma.
    Kim DW; Oh DY; Shin SH; Kang JH; Cho BC; Chung JS; Kim H; Park KU; Kwon JH; Han JY; Kim MJ; Bang YJ
    BMC Cancer; 2014 Nov; 14():795. PubMed ID: 25362970
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in urinary total metanephrine excretion in recurrent and malignant pheochromocytomas and secreting paragangliomas.
    Amar L; Peyrard S; Rossignol P; Zinzindohoue F; Gimenez-Roqueplo AP; Plouin PF
    Ann N Y Acad Sci; 2006 Aug; 1073():383-91. PubMed ID: 17102107
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiangiogenic therapies for pheochromocytoma and paraganglioma.
    Jimenez C; Fazeli S; Román-Gonzalez A
    Endocr Relat Cancer; 2020 Jul; 27(7):R239-R254. PubMed ID: 32369773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.